Recent Updates
Recently added Catalysts
EHTH Positive Sentiment Score: 76/100

Document eHealth, Inc. Announces Third Quarter 2025 Results Raises 2025 annual earnings guidance to reflect strong YTD performance Comments on strong start to the Annual Enrollment Period Completed extension of term loan

Key Takeaway: eHealth, Inc. announced its third quarter 2025 financial results, reporting a revenue decline of 8% but raising its annual earnings guidance due to strong performance thus far. The company noted a positive start to the Annual Enrollment Period, highlighting increased consumer demand and effective operational management. While the GAAP net loss improved year-over-year, challenges remain, particularly linked to changes in the Medicare Advantage market that have affected member counts. The firm also achieved financial flexibility by extending the term of its loan maturity.

Market Sentiment Analysis

POSITIVE FACTORS

  • eHealth raised its 2025 annual earnings guidance to reflect strong year-to-date performance.
  • The company reported positive early indicators for the Annual Enrollment Period (AEP).
  • Operational costs decreased, reflecting effective cost management strategies.
  • The company successfully amended its term loan to extend the maturity, providing enhanced financial flexibility.

CONCERNS & RISKS

  • Total revenue decreased by 8% compared to the same quarter in the previous year.
  • Lower Medicare Advantage approved members due to recent regulatory changes limiting dual-eligible beneficiaries.
  • The GAAP net loss, although improving, still stood at $31.7 million.

Full Press Release Details

eHealth, Inc. Announces Third Quarter 2025 Results
Raises 2025 annual earnings guidance to reflect strong YTD performance
Comments on strong start to the Annual Enrollment Period
Completed extension of term loan maturity providing additional financial flexibility
AUSTIN, Texas - November 5, 2025 - eHealth, Inc. (Nasdaq EHTH), a leading private online health insurance marketplace, today announced its financial results for the third quarter ended September 30, 2025.
CEO Comments
"As a new CEO, my immediate priority is clear deliver a strong AEP performance. We entered the enrollment season exceptionally well prepared-with a more experienced advisor force, a trusted and growing brand, and one of the broadest plan selections in the industry. In a period marked by significant disruption in the Medicare Advantage market, our breadth of offerings is a true differentiator, allowing us to support consumers as their coverage and needs evolve. Early AEP indicators are encouraging consumer demand is strong, and our branded messages resonate even stronger than a year ago. Our team is approaching AEP with flexibility and focus, ready to lean in where we see an opportunity to drive incremental growth at attractive economics." - Derrick Duke, Chief Executive Officer
Q3 2025 total revenue of $53.9 million decreased 8% compared to Q3 2024 total revenue of $58.4 million.
Lower Medicare Advantage ("MA") approved members as a result of the recent regulatory changes that limit dual-eligible beneficiaries from switching plans outside of the main enrollment periods.
Q3 2025 MA constrained lifetime value ("LTV") of commissions decreased 2% compared to Q3 2024.
Q3 2025 Medicare Supplement constrained LTV increased 33% compared to Q3 2024.
Q3 2025 positive net adjustment revenue of $12.2 million compared to $1.2 million in Q3 2024.
Q3 2025 total operating costs and expenses decreased 6% to $95.4 million compared to $101.6 million in Q3 2024.
25% reduction in consolidated and Medicare segment variable marketing spend in Q3 2025 compared to Q3 2024, reflecting proactive cost management strategies.
Q3 2025 customer care and enrollment expenses declined $2.5 million, or 6%, compared to Q3 2024, primarily reflecting execution of our flexible staffing strategy within our telesales organization, partially offset by costs associated with a more tenured benefit advisor group and increased number of retention advisors year-over-year.
Q3 2025 GAAP net loss of $31.7 million improved $10.8 million, compared to Q3 2024 GAAP net loss of $42.5 million.
Q3 2025 adjusted EBITDA(1) of $(34.0) million compared to Q3 2024 adjusted EBITDA(1) of $(34.8) million.
Cash, cash equivalents and marketable securities of $75.3 million as of September 30, 2025.
Commissions receivable balance of $907.7 million as of September 30, 2025.
Successfully completed our AEP preparations achieved our benefit advisor hiring and training targets, continued to strengthen and expand our brand-driven marketing strategy, and completed further enhancements to our omni-channel platform.
Amended term loan credit agreement to extend maturity date to January 2027 providing additional financial flexibility.
Note See the tables at the end of this press release for a reconciliation of our GAAP financial measures to our non-GAAP financial measures for the relevant periods and footnote (1) on page 14 at the end of this press release for definitions of our non-GAAP financial measures. Additionally, see accompanying footnotes on page 14 for additional definitions.
Said John Dolan, Chief Financial Officer "We continue to execute with discipline and agility in a dynamic environment. Our Q3 performance reflects strong operational focus on prudent cost management. Our performance through the end of September enabled us to raise our GAAP net income and adjusted EBITDA guidance ranges. The increase reflects the positive impact of net adjustment revenue and favorable operating costs relative to our internal expectations."
Based on information available as of November 5, 2025, we are revising our guidance for the full year ending December 31, 2025. These expectations are forward-looking statements and we assume no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth's annual and quarterly reports filed with the Securities and Exchange Commission.
The following guidance is for the full year ending December 31, 2025
Total revenue is expected to be in the range of $525.0 million to $565.0 million, consistent with our previously issued guidance.
GAAP net income is expected to be in the range of $9.0 million to $30.0 million compared to our prior guidance range of GAAP net income of $5.0 million to $26.0 million.
Adjusted EBITDA(1) is expected to be in the range of $60.0 million to $80.0 million compared to our prior guidance range of $55.0 million to $75.0 million.
Operating cash flow is expected to be in the range of $(25.0) million to $10.0 million, consistent with our previously issued guidance.
The above guidance includes the expected impact of positive net adjustment revenue which has been updated to be in the range of $40 million to $43 million to reflect the Q3 2025 positive net adjustment revenue, compared to the previous range of $29 million to $32 million.
Note See accompanying footnotes on page 14.
Webcast and Conference Call Information
A webcast and conference call will be held today, Wednesday, November 5, 2025 at 5 00 p.m. Eastern Time 4 00 p.m. Central Time. Individuals interested in listening to the conference call may do so by dialing (800) 549-8228. The participant passcode is 47090. The live and archived webcast of the call will also be available under "Events Presentations" on the Investor Relations page of our website at https ir.ehealthinsurance.com.
We're Matchmakers. For over 25 years, eHealth has helped millions of Americans find the healthcare coverage that fits their needs at a price they can afford. As a leading independent licensed insurance agency and advisor, eHealth offers access to over 180 health insurers, including national and regional companies.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations regarding our business, financial condition, operations and strategy our estimates regarding approved members and estimated memberships, in the aggregate and by product category our estimates regarding constrained lifetime values of commissions per approved member by product category our estimates regarding costs per approved member our 2025 annual guidance for total revenue, GAAP net income (loss), adjusted EBITDA and operating cash flow our estimates for positive net adjustment revenue and its expected impact on our 2025 annual guidance the expected impact of our efforts to prepare for the annual enrollment period, including our benefit advisor hiring and training targets and branding efforts our expectations regarding market opportunity, consumer demand and
our competitive advantage and other statements regarding our future operations, financial condition, prospects and business strategies.
These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 - Revenue from Contracts with Customers to make numerous assumptions that are based on historical trends and our management's judgment. These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.
The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to retain existing members and enroll new members during the annual healthcare open enrollment period, the Medicare annual enrollment period, the Medicare Advantage open enrollment period and other special enrollment periods changes in laws, regulations and guidelines, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans competition, including competition from government-run health insurance exchanges marketplaces, and other sources the seasonality of our business and the fluctuation of our operating results our ability to accurately estimate membership, lifetime value of commissions and commissions receivable changes in product offerings among carriers on our ecommerce platform and changes in our estimated conversion rate of an approved member to a paying member and the resulting impact of each on our commission revenue the concentration of our revenue with a small number of health insurance carriers our ability to execute on our growth strategy and other business initiatives changes in our senior management or other key employees our ability to recruit, train, retain and ensure the productivity of licensed insurance agents, or benefit advisors, and other personnel exposure to security risks and our ability to safeguard the security and privacy of confidential data our relationships with health insurance carriers the success of our carrier advertising and sponsorship program our success in marketing and selling health insurance plans and our unit cost of acquisition our ability to effectively manage our operations as our business evolves and execute on our business plan and other strategic initiatives the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products changes in the market for private health insurance consumer satisfaction of our service and actions we take to improve the quality of enrollments changes in member conversion rates changes in commission rates our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges and marketplaces our ability to derive desired benefits from investments in our business, including membership growth and retention initiatives our reliance on marketing partners the success and cost of our marketing efforts, including branding, online advertising, direct-to-consumer mail, email, social media, telephone, SMS text, television, radio and other marketing efforts timing of receipt and accuracy of commission reports payment practices of health insurance carriers dependence on our operations in China the restrictions in our debt obligations the restrictions in our investment agreement with our convertible preferred stock investor our ability to raise additional capital, including debt or equity financings, on terms acceptable to us or at all compliance with insurance, privacy, cybersecurity and other laws and regulations the outcome of litigation, government enforcement actions or regulatory inquiries in which we are or may from time to time be involved, including the complaint filed against us and certain defendants by the U.S. Attorney's Office for the District of Massachusetts on May 1, 2025 alleging the violation of the Federal False Claims Act the performance, reliability and availability of our information technology systems, ecommerce platform and underlying network infrastructure, including any new systems we may implement our ability to deploy new and evolving technologies, such as artificial intelligence public health crises, pandemics, natural disasters and other extreme events general economic and macroeconomic conditions, including the risks of potential delays, reductions or disruptions in payments from a prolonged government shutdown, inflation, recession, political events, instability or geopolitical tensions, tariffs and trade tensions or other international disputes, financial, banking and credit market disruptions our ability to effectively administer our self-insurance program and other risks and uncertainties related to our business. Other factors that could cause our operating, financial and other results to differ are described in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on the Investor Relations page of our website at https ir.ehealthinsurance.com and on the Securities and Exchange Commission's website at www.sec.gov.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Relations Contact
Kate Sidorovich, CFA
Senior Vice President, Investor Relations Corporate Development
investors ehealth.com
https ir.ehealthinsurance.com
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, unaudited)
September 30, 2025 December 31, 2024
Assets
Current assets
Cash and cash equivalents $ 63,089 $ 39,197
Short-term marketable securities 12,212 43,043
Accounts receivable 1,852 16,807
Contract assets - commissions receivable - current 208,426 242,467
Prepaid expenses and other current assets 17,288 12,961
Total current assets 302,867 354,475
Contract assets - commissions receivable - non-current 699,299 757,523
Property and equipment, net 4,939 4,437
Operating lease right-of-use assets 9,182 12,081
Restricted cash 3,090 3,090
Other assets 28,038 23,819
Total assets $ 1,047,415 $ 1,155,425
Liabilities, convertible preferred stock and stockholders' equity
Current liabilities
Accounts payable $ 6,215 $ 23,448
Accrued compensation and benefits 24,266 43,888
Accrued marketing expenses 5,558 16,612
Lease liabilities - current 7,769 7,732
Other current liabilities 7,430 4,331
Total current liabilities 51,238 96,011
Long-term debt 69,423 68,458
Deferred income taxes - non-current 21,860 38,870
Lease liabilities - non-current 15,540 20,731
Other non-current liabilities 4,885 5,418
Total liabilities 162,946 229,488
Convertible preferred stock 370,303 337,509
Stockholders' equity
Common stock 44 43
Additional paid-in capital 758,113 773,371
Treasury stock, at cost (199,998) (199,998)
Retained earnings (accumulated deficit) (43,815) 15,246
Accumulated other comprehensive loss (178) (234)
Total stockholders' equity 514,166 588,428
Total liabilities, convertible preferred stock and stockholders' equity $ 1,047,415 $ 1,155,425
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 % Change 2025 2024 % Change
Revenue
Commission $ 47,223 $ 48,222 (2) % $ 200,900 $ 185,996 8 %
Other 6,646 10,187 (35) % 26,870 31,233 (14) %
Total revenue 53,869 58,409 (8) % 227,770 217,229 5 %
Operating costs and expenses (a)
Marketing and advertising 24,395 29,665 (18) % 87,009 95,185 (9) %
Customer care and enrollment 36,814 39,321 (6) % 101,945 100,773 1 %
Technology and content 11,805 12,264 (4) % 35,760 38,613 (7) %
General and administrative 21,925 20,297 8 % 60,817 62,318 (2) %
Impairment, restructuring and other charges 455 61 646 % 2,010 9,409 (79) %
Total operating costs and expenses 95,394 101,608 (6) % 287,541 306,298 (6) %
Loss from operations (41,525) (43,199) 4 % (59,771) (89,069) 33 %
Interest expense (2,384) (2,859) 17 % (7,380) (8,517) 13 %
Other income, net 978 1,699 (42) % 3,894 6,425 (39) %
Loss before income taxes (42,931) (44,359) 3 % (63,257) (91,161) 31 %
Benefit from income taxes (11,240) (1,886) (16,118) (3,736)
Net loss (31,691) (42,473) 25 % (47,139) (87,425) 46 %
Preferred stock dividends (5,987) (5,643) (17,614) (16,603)
Change in preferred stock redemption value (6,903) (5,832) (19,583) (16,619)
Net loss attributable to common stockholders $ (44,581) $ (53,948) 17 % $ (84,336) $ (120,647) 30 %
Net loss per share attributable to common stockholders
Basic and diluted $ (1.46) $ (1.83) 20 % $ (2.78) $ (4.13) 33 %
Weighted-average number of shares used in per share
Basic and diluted 30,633 29,485 4 % 30,347 29,211 4 %
_____________________________ (a) Includes stock-based compensation expense as follows
Marketing and advertising $ 609 $ 437 $ 1,691 $ 1,792
Customer care and enrollment 339 452 935 1,487
Technology and content 666 845 2,034 2,598
General and administrative 2,308 2,745 6,927 9,248
Total stock-based compensation expense $ 3,922 $ 4,479 (12) % $ 11,587 $ 15,125 (23) %
Non-GAAP Results (1)
Adjusted EBITDA (1) $ (34,007) $ (34,832) 2 % $ (35,628) $ (52,024) 32 %
Adjusted EBITDA margin (1) (63) % (60) % (16) % (24) %
Note See accompanying footnotes on page 14.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 2025 2024
Operating activities
Net loss $ (31,691) $ (42,473) $ (47,139) $ (87,425)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization 447 473 1,384 1,481
Amortization of internally developed software 2,694 3,354 9,162 11,030
Stock-based compensation expense 3,922 4,479 11,587 15,125
Deferred income taxes (11,815) (1,709) (17,010) (4,340)
Impairment charges 455 - 868 7,413
Other non-cash items 41 74 (596) (43)
Changes in operating assets and liabilities
Accounts receivable 3 (4,681) 14,955 (1,871)
Contract assets - commissions receivable 9,325 17,885 92,811 104,582
Prepaid expenses and other assets (7,147) (11,327) (7,661) (9,896)
Accounts payable 516 509 (17,111) (1,965)
Accrued compensation and benefits 7,213 6,195 (19,621) (14,593)
Accrued marketing expenses 1,511 1,366 (11,054) (11,132)
Deferred revenue (1,200) (1,173) (872) 861
Accrued expenses and other liabilities 413 (2,255) 901 69
Net cash provided by (used in) operating activities (25,313) (29,283) 10,604 9,296
Investing activities
Capitalized internal-use software and website development costs (3,409) (3,191) (10,785) (8,070)
Purchases of property and equipment and other assets (214) (998) (2,107) (1,463)
Purchases of marketable securities (12,132) (48,489) (74,010) (85,880)
Proceeds from redemption and maturities of marketable securities 39,450 20,000 105,950 39,000
Net cash provided by (used in) investing activities 23,695 (32,678) 19,048 (56,413)
Financing activities
Payment of deferred financing costs (1,000) - (1,000) -
Net proceeds from exercise of common stock options and employee stock purchases - - 189 354
Repurchase of shares to satisfy employee tax withholding obligations (276) (450) (2,102) (2,301)
Principal payments in connection with leases - - - (4)
Payments of preferred stock dividends - - (2,906) (2,740)
Net cash used in financing activities (1,276) (450) (5,819) (4,691)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 63 99 59 118
Net increase (decrease) in cash, cash equivalents and restricted cash (2,831) (62,312) 23,892 (51,690)
Cash, cash equivalents and restricted cash at beginning of period 69,010 129,434 42,287 118,812
Cash, cash equivalents and restricted cash at end of period $ 66,179 $ 67,122 $ 66,179 $ 67,122
(in thousands, unaudited)
We evaluate our business performance and manage our operations as two distinct reporting segments Medicare and Employer and Individual ("E I"). The Medicare segment consists primarily of commissions earned as the broker of record from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible beneficiaries, including but not limited to, dental and vision insurance. Our commissions may include certain bonus payments, which are generally based on attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers. The Medicare segment also consists of amounts earned in connection with our advertising program for marketing and other services as well as amounts earned from our non-broker of record fee-based arrangements and our performance of various post-enrollment services for members. The E I segment consists primarily of commissions earned from our sale of individual and family plans ("IFP"), including qualified and non-qualified plans, small business health insurance plans and ancillary products sold to our non-Medicare-eligible consumers, including but not limited to, dental, vision and short-term insurance. To a lesser extent, the E I segment includes amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets on our website as well as our technology licensing activities.
We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operation in the annual budget and forecasting process along with evaluation of actual performance. Our CODM considers budget-to-actual variances on a monthly basis for our segment performance measures when making decisions about allocating capital and personnel to our segments. These performance measures include total segment revenue and segment gross profit (loss). Prior to the fourth quarter of 2024, we reported our measure of segment profitability as segment profit (loss). Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects.
Segment gross profit (loss) is calculated as total revenue for the applicable segment less variable marketing and advertising expenses, segment customer care and enrollment expenses ("CC E") and cost of revenue for the applicable segment. Variable marketing and advertising expenses represent costs incurred in member acquisition from our direct marketing and marketing partner channels and exclude fixed overhead costs, such as personnel related costs, consulting expenses and other operating costs allocated to the marketing and advertising department. Segment CC E expenses include expenses we incur in assisting applicants during the enrollment process and exclude operating costs allocated to the CC E department.
The results of our reportable segments are summarized for the periods presented below
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 % Change 2025 2024 % Change
Medicare
Total revenue $ 49,932 $ 53,221 (6) % $ 211,660 $ 194,857 9 %
Variable marketing and advertising (16,930) (22,512) 25 % (64,483) (71,030) 9 %
Medicare CC E (34,049) (36,320) 6 % (93,596) (91,954) (2) %
Cost of revenue (106) (13) * 158 (245) 164 %
Medicare segment gross profit (loss) $ (1,153) $ (5,624) 79 % $ 53,739 $ 31,628 70 %
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 % Change 2025 2024 % Change
Employer and Individual
Total revenue $ 3,937 $ 5,188 (24) % $ 16,110 $ 22,372 (28) %
Variable marketing and advertising (723) (936) 23 % (2,630) (2,410) (9) %
E I CC E (2,154) (2,320) 7 % (6,535) (6,732) 3 %
Cost of revenue (87) (89) 2 % (241) (300) 20 %
E I segment gross profit $ 973 $ 1,843 (47) % $ 6,704 $ 12,930 (48) %
* Percentage calculated is not meaningful.
(in thousands, unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 % Change 2025 2024 % Change
Consolidated
Total revenue $ 53,869 $ 58,409 (8) % $ 227,770 $ 217,229 5 %
Variable marketing and advertising (17,653) (23,448) 25 % (67,113) (73,440) 9 %
Segment CC E (36,203) (38,640) 6 % (100,131) (98,686) (1) %
Cost of revenue (193) (102) (89) % (83) (545) 85 %
Total segment gross profit (loss) $ (180) $ (3,781) 95 % $ 60,443 $ 44,558 36 %
A reconciliation of our segment gross profit (loss) to the Condensed Consolidated Statements of Operations for the periods presented is as follows
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 % Change 2025 2024 % Change
Total segment gross profit (loss) $ (180) $ (3,781) 95 % $ 60,443 $ 44,558 36 %
Other marketing and advertising (a) (6,549) (6,115) (7) % (19,813) (21,200) 7 %
Other CC E (b) (611) (681) 10 % (1,814) (2,087) 13 %
Technology and content (11,805) (12,264) 4 % (35,760) (38,613) 7 %
General and administrative (21,925) (20,297) (8) % (60,817) (62,318) 2 %
Impairment, restructuring and other charges (455) (61) (646) % (2,010) (9,409) 79 %
Interest expense (2,384) (2,859) 17 % (7,380) (8,517) 13 %
Other income, net 978 1,699 (42) % 3,894 6,425 (39) %
Loss before income taxes $ (42,931) $ (44,359) 3 % $ (63,257) $ (91,161) 31 %
(a)Other marketing and advertising costs consist of fixed marketing and advertising, previously capitalized labor, depreciation and share-based compensation costs.
(b)Other CC E costs consist of previously capitalized labor, depreciation and share-based compensation costs.
(in thousands, unaudited)
Our commission revenue results from approval of an application from health insurance carriers, which we define as our customers under Accounting Standards Codification 606 - Revenue from Contracts with Customers ("ASC 606"). Our commission revenue is primarily comprised of commissions from health insurance carriers which is computed using the estimated constrained lifetime values of commission payments that we expect to receive. Our commissions may include certain bonus payments, which are generally based on our attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers.
The following table presents commission revenue by product for the periods indicated
Three Months Ended September 30, % Change Nine Months Ended September 30, % Change
2025 2024 2025 2024
Medicare
Medicare Advantage $ 37,713 $ 39,463 (4) % $ 150,963 $ 143,627 5 %
Medicare Supplement 2,309 2,312 - % 24,199 11,835 104 %
Medicare Part D 1,561 843 85 % 2,956 6,238 (53) %
Total Medicare 41,583 42,618 (2) % 178,118 161,700 10 %
Individual and Family
Non-Qualified Health Plans (a) (125) (199) (37) % 359 1,834 (80) %
Qualified Health Plans (a) (64) 602 (111) % 1,299 3,358 (61) %
Total Individual and Family (189) 403 (147) % 1,658 5,192 (68) %
Ancillary 3,274 2,036 61 % 11,355 7,279 56 %
Small Business 2,251 2,268 (1) % 7,982 8,447 (6) %
Commission Bonus and Other 304 897 (66) % 1,787 3,378 (47) %
Total Commission Revenue $ 47,223 $ 48,222 (2) % $ 200,900 $ 185,996 8 %
(a)Total revenue for non-qualified and qualified health plans was negative due to $(0.5) million and $(0.3) million, respectively, of net commission revenue from members approved in prior periods for the three months ended September 30, 2025. Total revenue for non-qualified health plans was negative due to $(0.6) million of net commission revenue from members approved in prior periods for the three months ended September 30, 2024.
The following table presents a summary of commission revenue by segment for the periods indicated
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 2025 2024
Medicare
Commission revenue from members approved during the period $ 31,402 $ 42,324 $ 146,304 $ 152,017
Net commission revenue from members approved in prior periods (a) 12,081 1,090 39,135 12,773
Total Medicare segment commission revenue 43,483 43,414 185,439 164,790
Employer and Individual
Commission revenue from members approved during the period 1,881 2,848 7,659 11,790
Commission revenue from renewals of small business members during the period 1,737 1,852 6,479 7,022
Net commission revenue from members approved in prior periods (a) 122 108 1,323 2,394
Total Employer and Individual segment commission revenue 3,740 4,808 15,461 21,206
Total commission revenue $ 47,223 $ 48,222 $ 200,900 $ 185,996
(a)For all existing cohorts approved in prior periods, we reassess assumptions for our constrained lifetime value ("LTV") of commissions on a quarterly basis and compare to the most current constrained LTV recognized on these cohorts. To the extent there is an indication of a change to expected cash collections for these cohorts, net commission revenue from members approved in prior periods, also referred to as net adjustment revenue, is recorded to adjust revenue previously recognized for the affected cohorts. Net adjustment revenue includes both increases and reductions to revenue however, adjustments increasing revenue are only recognized when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.
SUMMARY OF SELECTED METRICS
Selected Metrics - Third Quarter of 2025
Three Months Ended September 30, % Change
2025 2024
Approved Members (2)
Medicare
Medicare Advantage 28,645 40,141 (29) %
Medicare Supplement 1,393 1,438 (3) %
Medicare Part D 1,129 1,292 (13) %
Total Medicare 31,167 42,871 (27) %
Individual and Family 1,872 2,872 (35) %
Ancillary 12,003 11,382 5 %
Small Business 1,228 1,141 8 %
Total Approved Members 46,270 58,266 (21) %
Constrained Lifetime Value of Commissions per Approved Member (3)
Medicare (a)
Medicare Advantage $ 975 $ 990 (2) %
Medicare Supplement 1,467 1,105 33 %
Medicare Part D 168 222 (24) %
Individual and Family
Non-Qualified Health Plans 300 314 (4) %
Qualified Health Plans 268 311 (14) %
Ancillary
Short-term 110 144 (24) %
Dental 125 118 6 %
Vision 78 78 - %
Small Business 254 249 2 %
(a) Constraints for Medicare Advantage, Medicare Supplement and Medicare Part D were 5.5%, 4% and 7%, respectively, for the three months ended September 30, 2025. Constraints for Medicare Advantage, Medicare Supplement and Medicare Part D were 5.5%, 9% and 7%, respectively, for the three months ended September 30, 2024.
Expense Metrics per Approved Member (4)
Medicare Plans
CC E cost per Medicare Advantage ("MA")-equivalent approved member $ 930 $ 719 29 %
Variable marketing cost per MA-equivalent approved member 559 537 4 %
Total acquisition cost per MA-equivalent approved member $ 1,489 $ 1,256 19 %
Individual and Family Plans ("IFP")
CC E cost per IFP-equivalent approved member $ 433 $ 359 21 %
Variable marketing cost per IFP-equivalent approved member 104 118 (12) %
Total acquisition cost per IFP-equivalent approved member $ 537 $ 477 13 %
Note See accompanying footnotes on page 14.
SUMMARY OF SELECTED METRICS
Selected Metrics - Nine Months Ended September 30, 2025
Nine Months Ended September 30, % Change
2025 2024
Approved Members (2)
Medicare
Medicare Advantage 141,884 143,529 (1) %
Medicare Supplement 5,688 9,574 (41) %
Medicare Part D 5,149 6,335 (19) %
Total Medicare 152,721 159,438 (4) %
Individual and Family 9,751 13,540 (28) %
Ancillary 41,288 36,410 13 %
Small Business 3,256 3,705 (12) %
Total Approved Members 207,016 213,093 (3) %
As of September 30, % Change
2025 2024
Estimated Membership (5)
Medicare (6)
Medicare Advantage 579,914 583,970 (1) %
Medicare Supplement 90,596 95,153 (5) %
Medicare Part D 174,970 194,303 (10) %
Total Medicare 845,480 873,426 (3) %
Individual and Family (6) 62,678 75,871 (17) %
Ancillary (6) 173,835 168,953 3 %
Small Business (7) 36,528 41,172 (11) %
Total Estimated Membership 1,118,521 1,159,422 (4) %
Note See accompanying footnotes on page 14.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and Expenses(1) (in thousands)
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 2025 2024
GAAP marketing and advertising expense $ 24,395 $ 29,665 $ 87,009 $ 95,185
Stock-based compensation expense (609) (437) (1,691) (1,792)
Non-GAAP marketing and advertising expense (1) $ 23,786 $ 29,228 $ 85,318 $ 93,393
GAAP customer care and enrollment expense $ 36,814 $ 39,321 $ 101,945 $ 100,773
Stock-based compensation expense (339) (452) (935) (1,487)
Non-GAAP customer care and enrollment expense (1) $ 36,475 $ 38,869 $ 101,010 $ 99,286
GAAP technology and content expense $ 11,805 $ 12,264 $ 35,760 $ 38,613
Stock-based compensation expense (666) (845) (2,034) (2,598)
Non-GAAP technology and content expense (1) $ 11,139 $ 11,419 $ 33,726 $ 36,015
GAAP general and administrative expense $ 21,925 $ 20,297 $ 60,817 $ 62,318
Stock-based compensation expense (2,308) (2,745) (6,927) (9,248)
Non-GAAP general and administrative expense (1) $ 19,617 $ 17,552 $ 53,890 $ 53,070
GAAP operating costs and expenses $ 95,394 $ 101,608 $ 287,541 $ 306,298
Stock-based compensation expense (3,922) (4,479) (11,587) (15,125)
Impairment, restructuring and other charges (455) (61) (2,010) (9,409)
Non-GAAP operating costs and expenses (1) $ 91,017 $ 97,068 $ 273,944 $ 281,764
Reconciliation of GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA(1) (in thousands) and Adjusted EBITDA Margin(1)
Three Months Ended September 30, Nine Months Ended September 30,
2025 2024 2025 2024
GAAP net loss attributable to common stockholders $ (44,581) $ (53,948) $ (84,336) $ (120,647)
Preferred stock dividends 5,987 5,643 17,614 16,603
Change in preferred stock redemption value 6,903 5,832 19,583 16,619
GAAP net loss (31,691) (42,473) (47,139) (87,425)
Stock-based compensation expense 3,922 4,479 11,587 15,125
Depreciation and amortization 3,141 3,827 10,546 12,511
Impairment, restructuring and other charges 455 61 2,010 9,409
Interest expense 2,384 2,859 7,380 8,517
Other income, net (978) (1,699) (3,894) (6,425)
Benefit from income taxes (11,240) (1,886) (16,118) (3,736)
Adjusted EBITDA (1) $ (34,007) $ (34,832) $ (35,628) $ (52,024)
Net loss margin (59) % (73) % (21) % (40) %
Adjusted EBITDA margin (1) (63) % (60) % (16) % (24) %
Note See accompanying footnotes on page 14.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of Guidance GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA(1) (in millions)
Full Year 2025 Guidance
Low High
GAAP net loss attributable to common stockholders $ (41.0) $ (20.0)
Impact from preferred stock 50.0 50.0
GAAP net income 9.0 30.0
Stock-based compensation expense 15.0 12.0
Depreciation and amortization 18.0 17.0
Interest expense 11.0 10.0
Other income, net (3.0) (3.0)
Provision for income taxes 10.0 14.0
Adjusted EBITDA (1) $ 60.0 $ 80.0
Note See accompanying footnotes on page 14.
Footnotes to Preceding Financial Statements and Metrics
(1)Non-GAAP Financial Information
This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). To supplement eHealth's condensed consolidated financial statements presented in accordance with GAAP, eHealth presents investors with non-GAAP financial measures, including non-GAAP operating costs and expenses, adjusted EBITDA and adjusted EBITDA margin.
Non-GAAP operating costs and expenses are calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan from the respective GAAP operating costs and expenses. Total non-GAAP operating costs and expenses is calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan and impairment, restructuring and other charges from GAAP total operating costs and expenses.
Adjusted EBITDA is calculated by excluding dividends for preferred stock and change in preferred stock redemption value (together the "impact from preferred stock"), provision for (benefit from) income taxes, depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, interest expense, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Frequently Asked Questions

What were eHealth's Q3 2025 total revenues?

eHealth reported total revenues of $53.9 million for Q3 2025.

How did eHealth's Q3 2025 GAAP net loss compare to 2024?

The Q3 2025 GAAP net loss was $31.7 million, improving from $42.5 million in 2024.

What change did eHealth make to its term loan?

eHealth amended its term loan to extend the maturity date to January 2027.

What is eHealth's revenue guidance for 2025?

eHealth expects revenue between $525.0 million and $565.0 million for 2025.

How much did eHealth's adjusted EBITDA change in Q3 2025?

Adjusted EBITDA for Q3 2025 was $(34.0) million, slightly improved from $(34.8) million.

Last updated: Nov 5, 2025